We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vertex Pharmaceuticals Incorporated today announced the FDA approved expanded use of Trikafta to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance
The Australian Therapeutic Goods Administration (TGA) has approved the use of Vertex Pharmaceutical’s Trikafta (elexacaftor, tezacaftor, ivacaftor and ivacaftor) for people with cystic fibrosis (CF) aged 12 years and above.